A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions

NCT ID: NCT06487416

Last Updated: 2024-07-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 186 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-10
• Study Completion Date: 2024-10-31

Brief Summary

Primary Objective: To evaluate the pharmacokinetics and bioequivalence of the test products Tiotropium Bromide Inhalation Powder (Strength: 18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) and reference products Tiotropium Bromide Inhalation Powder (Spiriva®Handihaler®, Strength: 18 mcg, manufactured by Boehringer Ingelheim Pharma GmbH and CO.KG) by oral inhalation in healthy participants under fasting conditions.

Secondary Objective: To assess the safety of the test products Tiotropium Bromide Inhalation Powder (Strength: 18 mcg) and reference products Tiotropium Bromide Inhalation Powder (Spiriva®Handihaler®, Strength: 18 mcg) in healthy participants.

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Tiotropium Bromide Inhalation Powder

Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 microgram (mcg), as tiotropium, equivalent to 22.5 microgram of tiotropium bromide monohydrate).

The subjects randomly received single oral dose of tiotropium bromide inhaling powder

Group Type: EXPERIMENTAL

Tiotropium Bromide Inhalation Powder

Intervention Type: DRUG

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

Spiriva®Handihaler®

Reference Product (Spiriva®Handihaler®, Strength: 18 microgram, as tiotropium, equivalent to 22.5 microgram of tiotropium bromide monohydrate).

The subjects randomly received single oral dose of Spiriva®Handihaler®

Group Type: EXPERIMENTAL

Spiriva®Handihaler®

Intervention Type: DRUG

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

Interventions

Tiotropium Bromide Inhalation Powder

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

Intervention Type: DRUG

Spiriva®Handihaler®

By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Able to give signed Informed Consent Form before the trial, and fully understand the trial content, process and possible adverse drug reactions (ADRs);
• Able to complete the trial in compliance with the protocol;
• Participants (including males) willing to adopt effective contraceptive methods and with no pregnancy plan from 14 days before screening to 3 months after the last scheduled visit;
• Males and females between 18 and 55 years old, inclusive;
• At least 50 kg for males, 45 kg for females, with a Body Mass Index (BMI) = Weight/Height2 (kg/m2) between 19.0-26.0 kg/m2, inclusive;
• No history of cardiac, hepatic, renal, ophthalmology and otorhinolaryngology, respiratory system, urogenital system, digestive tract, nervous system, mental and metabolic disorders, etc.

Exclusion Criteria

• With ≥ 5 cigarettes per day on average within 3 months before screening, or not able to quit smoking during the trial, or a positive result for urine nicotine test;
• Be allergic to tiotropium, atropine or its derivatives (e.g., ipratropium, oxitropium) or any excipient of tiotropium bromide inhalation powder; or allergic constitution (be allergic to two or more drugs, food and pollen allergy); or with specific allergy history (asthma, urticaria, eczema, etc.);
• A history of alcohol abuse (alcohol consumption of more than 14 units per week: 1 unit of alcohol = 285 mL beer, or 25 mL spirits, or 100 mL wine);
• Blood donation or massive blood loss (≥400 mL) within 3 months before the initial administration; Or any blood donation plan from screening until 1 month after the last administration;
• Participants who have an acute upper respiratory tract infection within 2 weeks prior to receiving investigational product;
• History of any clinically significant diseases or any other diseases that could interfere with the study results, including but not limited to the circulatory system, gastrointestinal system, urinary system (such as history of prostate hypertrophy, bladder neck obstruction, urinary retention, etc.), respiratory system (such as acute onset of chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pulmonary edema, pulmonary interstitial disease, bronchospastic pulmonary disease, bronchial asthma, etc.), ophthalmology (such as: glaucoma, etc.), nervous system, immune system, endocrine system, malignant tumor, mental and metabolic abnormalities; or with history of nasopharyngitis, throat ulcers, edema, or history of throat, tracheal/bronchial and lung surgery in the past;
• Participants who have Sjogren's syndrome and habitual constipation;
• Function test: the forced expiratory volume in one second measured value / the forced expiratory volume in one second predicted value ≤80% or the forced expiratory volume in one second / forced vital capacity ≤80%;
• Any prescription medication within 14 days before the initial administration;
• Any over-the-counter (OTC) medication or Chinese herbal medicine or health supplementary within 7 days before the initial administration;
• Consumption of any special diets (such as grapefruit), or strenuous exercise engagement, or other factors affecting drug absorption, distribution, metabolism and excretion within 7 days before the initial administration;
• Participation in other drug clinical trials within 3 months before the initial administration;
• Any clinically significant abnormality findings, as judged by a clinical physician, such as physical examination, vital signs, electrocardiogram, chest X-ray examination and laboratory tests;
• Positive results of hepatitis B surface antigen, hepatitis C antibody, and HIV antibody or syphilis;
• Consumption of chocolate or any food/beverage containing caffeine or rich in xanthine within 48 h before the initial administration;
• Consumption of any products containing alcohol within 48 h before the initial administration, or a positive result of the alcohol breath test;
• A positive result of the drug abuse test, or a history of drug abuse in the past 5 years, or intake of any narcotic drugs within 3 months prior to the trial;
• A positive result of the pregnancy test, or in lactation during screening or the test period for female participants;
• History of fainting at needle or blood;
• Not tolerable on venipuncture, or a history of difficulty in venous blood collection;
• Special requirements and unable to follow the unified diet, or lactose/galactose intolerant;
• Unable to participate in this trial for participants' own reasons;
• Participants who cannot use the powder inhalers correctly after training;
• Other conditions in which participants are not suitable for the trial determined by investigators.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The First Affiliated Hospital of Bengbu Medical University

Bengbu, Anhui, China

Countries

China

Other Identifiers

STXA-BE-04

Identifier Type: -

Identifier Source: org_study_id